Evaxion A/S
EVAX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001828253
No open-market purchases or sales by Evaxion A/S insiders were filed in the last 90 days; 19 institutions reported holding it in 13F filings for Q2 2026, worth $4.93M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +2 vs. previous quarter
- 19
- 13F valueReported value at the end of Q2 2026
- $4.93M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding EVAX, Q2 2026
No superinvestor reported holding EVAX at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Evaxion A/S insiders from Form 4, newest first.
No open-market purchases or sales by Evaxion A/S insiders are on file.
Top 10 13F holders, Q2 2026
The largest institutional positions in Evaxion A/S at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Merck & Co., Inc. | 1,214,126 | $3.76M | 0.71% | 00.0% | Unchanged |
| Ikarian Capital, LLC | 74,698 | $231.6K | 0.04% | 00.0% | Unchanged |
| Rathbone Brothers plc | 45,723 | $141.7K | 0.00% | −45,723−50.0% | Reduced |
| Citadel Advisors LLC | 36,584 | $113.4K | 0.00% | +18,811+105.8% | Added |
| Renaissance Technologies LLC | 33,800 | $104.8K | 0.00% | −5,425−13.8% | Reduced |
| Annis Gardner Whiting Capital Advisors, LLC | 30,000 | $93.0K | 0.01% | 00.0% | Unchanged |
| J. Safra Sarasin Holding AG | 22,896 | $71.0K | 0.00% | +22,896 | New |
| Rhumbline Advisers | 21,849 | $67.7K | 0.00% | +190+0.9% | Added |
| Jane Street Group, LLC | 20,581 | $63.8K | 0.00% | +20,581 | New |
| Boothbay Fund Management, LLC | 18,426 | $57.1K | 0.00% | 00.0% | Unchanged |